| 摘要 |
<p>The present invention relates to novel anhydrous amorphous forms of [R-(E)-1-[[[l-[3-[2-[7-chloro-2-quinolinyl] ethenyl] phenyl]-3-[2-(1-hydroxy-l-methylethyl) phenyl] propyl] thio] methyl] cyclopropaneacetic acid alkali salts (Montelukast alkali salts) to processes for their preparation, to compositions containing them and to methods of treatment using the same. Montelukast is a leukotriene antagonist, is useful as anti-asthmatic, anti-allergic, anti-inflammatory and cytoprotective agent. Montelukast is represented by the formula (I).</p> |
